- Home
- LLY vs JPM Comparison
LLY vs JPM Comparison
Compare LLY & JPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LLY | JPM |
|---|---|---|
| Founded | 1876 | 1799 |
| Country | United States | United States |
| Employees | N/A | 320079 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.6B | 900.8B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | LLY | JPM |
|---|---|---|
| Price | $1,191.86 | $356.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 15 |
| Target Price | ★ $1,218.84 | $331.93 |
| AVG Volume (30 Days) | 2.0M | ★ 7.6M |
| Earning Date | 04-30-2026 | 04-14-2026 |
| Dividend Yield | 0.81% | ★ 1.94% |
| EPS Growth | ★ 95.99 | N/A |
| EPS | ★ 16.19 | N/A |
| Revenue | ★ $65,179,000,000.00 | N/A |
| Revenue This Year | $27.15 | $18.51 |
| Revenue Next Year | $16.04 | $4.11 |
| P/E Ratio | $141.50 | ★ $15.42 |
| Revenue Growth | ★ 44.70 | N/A |
| 52 Week Low | $623.78 | $279.10 |
| 52 Week High | $1,249.45 | $363.00 |
Technical Indicators
Market Signals| Indicator | LLY | JPM |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 67.78 |
| Support Level | $1,032.70 | $323.83 |
| Resistance Level | $1,240.73 | N/A |
| Average True Range (ATR) | 34.58 | 6.22 |
| MACD | -3.78 | 0.30 |
| Stochastic Oscillator | 78.01 | 94.93 |
Price Performance
Historical ComparisonAbout LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About JPM JP Morgan Chase & Co.
JPMorgan is a leading global financial services firm with operations in 66 countries and over 318,000 employees as of year-end 2025. Under the JPMorgan brands, the bank holding company boasts a $4.9 trillion balance sheet and $2.68 trillion in deposits, as of March 2026. The firm generates its revenue across three core operating segments: consumer and community banking, the commercial and investment bank, and asset and wealth management. It maintains the top global ranking in investment banking fees with an 8.4% market share, serves millions of consumers through its network of over 5,000 US branches, and manages over $7.1 trillion in client assets within its wealth and asset management franchise.